3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
10
Terminated
5
Unknown
2
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
32
Brain Neoplasms
21
Carcinoma, Non-Small-Cell Lung
19
Neoplasm Metastasis
17
Lung Neoplasms
15
Carcinoma, Hepatocellular
13
Breast Neoplasms
10
Pancreatic Neoplasms
9
Melanoma
9
Carcinoma, Renal Cell
9
Neoplasms
7
Colorectal Neoplasms
7
Spinal Cord Neoplasms
3
Small Cell Lung Carcinoma
3
Prostate Cancer Metastatic
3
Nasopharyngeal Carcinoma
3
Kidney Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Unresectable Locally Recurrent Rectal Cancer
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Radiation Injuries
2
Osteosarcoma
2
Oligometastatic Prostate Cancer
2
Neuroma, Acoustic
2
Neoplasms by Site
2
Klatskin Tumor
2
Head and Neck Neoplasms
2
Interventions
Bevacizumab
9
pembrolizumab
5
lenvatinib
5
durvalumab
5
atezolizumab
5
tremelimumab
3
fludarabine
3
camrelizumab
3
apatinib
3
Ipilimumab
3
Cyclophosphamide
3
regorafenib
2
Riluzole
2
Radiotherapy
2
Nivolumab
2
Magnetic Resonance Imaging
2
Idarubicin
2
Blood Specimen Collection
2
Biopsy
2
yttrium chloride
1
trastuzumab deruxtecan
1
spartalizumab
1
sintilimab
1
pertuzumab
1
ferric carboxymaltose
1
epigallocatechin gallate
1
donafenib
1
cemiplimab
1
brodalumab
1
Yttrium-90
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Liver Neoplasms
×
Radiosurgery
×
Clear all
NCT06725121
2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2
Recruiting
48 enrolled